MedTrace Logo

Flash Mob Study With Regard to Travel Willingness Among Patients With Cancer

NCT05940753 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2023-07-11

No results posted yet for this study

Summary

This is a cross-sectional study in the form of a flash mob study, in which an inventory will be made on 13 and 14 March 2023 of the willingness to travel of oncology patients in the participating hospitals. Patients who have an appointment with an internist-oncologist or oncology specialist nurse at the outpatient clinic or by telephone and patients who come to day treatment unit for medical oncology are asked to participate. Willingness to travel is examined by means of a survey, in which a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey.

Conditions

Interventions

OTHER

Survey about travel willingness regarding cancer treatment and follow-up

No intervention. Willingness to travel is examined through a survey. The survey will be conducted digitally, but may also be done on paper. In the survey a minimal set of categorized patient data (e.g. age, gender, level of education) is collected as part of the survey. For patients who cannot independently complete the questionnaire (for example due to low literacy skills), a volunteer, medical student or researcher is allowed to help the patient.

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • An KL Reyners, MD, PhD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-13
Primary Completion
2023-05-01
Completion
2023-05-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05940753 on ClinicalTrials.gov